Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks’ synthetic biology foundry files dense reports that mix government biosecurity contracts, milestone-based collaboration revenue, and intricate share-based compensation tables—information that can overwhelm even seasoned analysts. If you have ever searched for “Ginkgo Bioworks insider trading Form 4 transactions” or wondered how to decode a 300-page 10-K, you know the challenge.
Stock Titan solves that problem. Our platform pulls every filing—10-K, 10-Q, 8-K, S-1, DEF 14A and more—directly from EDGAR, then applies AI-powered summaries that turn jargon into plain English. Need the Ginkgo Bioworks quarterly earnings report 10-Q filing? We highlight Foundry capacity metrics and Cell Engineering backlog in seconds. Tracking management moves? Receive Ginkgo Bioworks Form 4 insider transactions real-time, complete with context so you can spot trends before they hit the headlines.
Use cases investors rely on daily:
- Compare Biosecurity and Cell Engineering revenue in the latest Ginkgo Bioworks annual report 10-K simplified.
- Monitor Ginkgo Bioworks executive stock transactions Form 4 alongside option grant details in the proxy statement executive compensation.
- See contract awards and lab expansions inside Ginkgo Bioworks 8-K material events explained.
- Dive deeper with Ginkgo Bioworks earnings report filing analysis generated by our AI.
Whether you’re understanding Ginkgo Bioworks SEC documents with AI for the first time or refining a valuation model, Stock Titan’s real-time updates and expert commentary keep you ahead without wading through technical appendices.
Form 144 Notice of Proposed Sale filed by Austin Che of Ginkgo Bioworks Holdings (NYSE: DNA) indicates planned sale of 99 Class A shares with an aggregate market value of $834.57, to be executed through Fidelity Brokerage Services around June 23, 2025.
The shares were originally acquired on October 12, 2022, through restricted stock vesting as compensation. The filing reveals extensive recent trading activity by the seller, with systematic sales of 99 shares per transaction over the past three months (March-June 2025), totaling 57 transactions.
Notable trading patterns show:
- Share prices ranging from $5.15 to $9.51 per share
- Consistent selling volume of 99 shares per trade
- Recent price appreciation trend in June 2025, with transactions reaching $8-9 per share
- Total outstanding shares: 46,344,630
Form 144 filing for Ginkgo Bioworks Holdings details proposed sale of securities by insider Austin Che. Key details:
- Proposed sale of 99 Class A shares through Fidelity Brokerage Services, with aggregate market value of $857.34
- Shares were acquired on October 12, 2022 through restricted stock vesting as compensation
- Extensive trading history shows consistent sales of 99 shares per transaction from March-June 2025
- Sale prices have ranged from $5.16 to $9.51 per share over the past 3 months
- Total shares outstanding: 46,344,630
The planned sale represents a continuation of a systematic selling pattern, with the insider executing regular small-volume transactions. Recent trading shows increasing share prices, with June 2025 transactions averaging higher values than earlier months.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What is the core business of Ginkgo Bioworks?
Which key segments does Ginkgo organize its operations into?
How does Ginkgo Bioworks generate revenue?
What industries benefit from Ginkgo's services?
How does Ginkgo incorporate advanced technology into its offerings?
How is Ginkgo differentiated from its competitors?
Can you elaborate on Ginkgo's approach to synthetic biology?
Who are the typical clients of Ginkgo Bioworks?
